8-K: Precision BioSciences Reports Positive Clinical Data and Financial Results for 2024, Extends Cash Runway into Second Half of 2026

Precision BioSciences announces positive clinical data from its ARCUS gene editing platform and reports its financial results for the fourth quarter and fiscal year ended December 31, 2024, projecting a cash runway into the second half of 2026.

Summary

• Precision BioSciences announced financial results for Q4 and fiscal year 2024, along with a business update.
• The company reported the first in vivo clinical validation for its ARCUS gene editing platform across two programs: PBGENE-HBV and ECUR-506.
• The Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, a gene editing technology for Hepatitis B, commenced in Q4 2024.
• PBGENE-HBV demonstrated safety and antiviral activity, with a reduction in Hepatitis B surface antigen after one administration at the lowest dose level.
• iECURE, a partner, announced a complete clinical response in the first infant dosed in a Phase 1/2 clinical trial for Ornithine Transcarbamylase (OTC) Deficiency.
• The company's cash runway is expected to extend into the second half of 2026, enabling achievement of key Phase 1 clinical inflection points across its in vivo gene editing programs.
• Total revenues for the year ended December 31, 2024, were $68.7 million, compared to $48.7 million in 2023.
• Research and development expenses for the year ended December 31, 2024, were $59.6 million, compared to $53.4 million in 2023.
• Net income for the year ended December 31, 2024, was $7.2 million, compared to a net loss of $61.3 million in 2023.
• As of December 31, 2024, Precision had approximately $108.5 million in cash, cash equivalents, and restricted cash.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical data, increased revenues, and a strong cash position; the company's progress in gene editing and strategic partnerships contribute to a favorable sentiment.

Positives

• Clinical validation of the ARCUS gene editing platform has been achieved.
• The Phase 1 trial for PBGENE-HBV has commenced, marking a significant milestone.
• Early data from the PBGENE-HBV trial shows promising antiviral activity and safety.
• A partner program, iECURE-OTC, demonstrated a complete clinical response in a patient with OTC deficiency.
• The company's cash position is strong, providing a runway into the second half of 2026.
• Revenues increased significantly in 2024 compared to 2023.
• The company achieved net income in 2024, a substantial turnaround from the previous year's net loss.

Negatives

• Revenues for the quarter ended December 31, 2024, were $0.6 million, compared to $7.0 million for the quarter ended December 31, 2023.
• The net loss from continuing operations was $17.8 million for the quarter ended December 31, 2024, compared to $13.4 million for the quarter ended December 31, 2023.

Risks

• The company's success depends on the progression and success of its programs and product candidates.
• There are risks associated with clinical trials, including the ability to enroll patients and potential safety concerns.
• The company faces competition in the gene editing, biopharmaceutical, and biotechnology fields.
• The company's cash runway depends on various factors, including operational receipts and the availability of its at-the-market (ATM) facility.
• The company's reliance on third parties, including suppliers and manufacturers, poses a risk.

Future Outlook

Precision BioSciences expects its existing cash and cash equivalents, upfront and potential near-term cash from CAR T transactions, along with expected operational receipts, continued fiscal and operating discipline, and availability of its at-the-market (ATM) facility to extend its cash runway into the second half of 2026; the company plans to provide ongoing updates on the full low-dose cohort for the PBGENE-HBV study, including multiple dose administrations, and data at higher dose levels throughout 2025.

Management Comments

• '2024 was a transformational year for Precision BioSciences as we solidified ourselves as a leading in vivo gene editing company, and we now have clinical data from two differentiated ARCUS based programs,' said Michael Amoroso, President and Chief Executive Officer of Precision BioSciences.
• Mr. Amoroso added, 'We have already completed dosing of the first patient cohort establishing both safety and early efficacy for PBGENE-HBV at the lowest dose level in the Phase 1 clinical trial and have commenced subsequent administrations.'
• Cassie Gorsuch, PhD, Chief Scientific Officer of Precision BioSciences, stated that initial clinical data in the first cohort of patients was consistent with the HBsAg reductions observed in preclinical non-human primate models and that PBGENE-HBV appears to be working by its intended mechanism of eliminating the source of viral replication in cccDNA while inactivating integrated disease.

Industry Context

Precision BioSciences is positioning itself as a leader in the in vivo gene editing space, particularly with its ARCUS platform; the company's focus on HBV and OTC deficiency addresses significant unmet medical needs; the competitive landscape includes companies developing other gene editing technologies, such as CRISPR/Cas9, but Precision highlights the advantages of its ARCUS platform.

Comparison to Industry Standards

• The ARCUS platform is being compared to CRISPR/Cas9, base editors, and prime editors, with Precision highlighting ARCUS's ability to penetrate mitochondrial membranes and target mutant mitochondrial DNA without requiring a guide RNA.
• The company's PBGENE-HBV program is the first potentially curative gene editing program to enter the clinic specifically designed to eliminate cccDNA and inactivate integrated HBV DNA, setting it apart from other downstream targeting modalities.
• iECURE's ECUR-506 program for OTC deficiency is showing promising results, with a complete clinical response in the first patient dosed, which is a significant achievement in this rare disease.

Management Changes

Stakeholder Impact

• Shareholders: The positive clinical data and financial results are likely to be viewed favorably by shareholders.
• Employees: The company's progress and strong financial position could improve employee morale and job security.
• Patients: The development of new gene editing therapies could provide hope for patients with chronic Hepatitis B, OTC deficiency, and other genetic diseases.
• Partners: The company's partnerships with iECURE and Novartis are expected to continue to advance the development of new therapies.

Next Steps

• Precision plans to complete subsequent administrations in all cohort 1 patients while in parallel expanding to the next higher dose cohorts for PBGENE-HBV.
• The company plans to provide ongoing updates on the full low-dose cohort, including multiple dose administrations, and data at higher dose levels throughout 2025.
• Precision plans to present new data for PBGENE-3243 while advancing the program toward a CTA and/or IND.
• iECURE expects to finish enrollment in 2025 and provide complete data for the ECUR-506 program in the first half of 2026.

Key Dates

Keywords

gene editing, ARCUS, PBGENE-HBV, clinical trial, Hepatitis B, iECURE, OTC deficiency, financial results, cash runway, Precision BioSciences